Early Mesothelioma Vaccine Testing Shows Promise
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine. The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave […]
The post Early Mesothelioma Vaccine Testing Shows Promise appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.